March 10, 2009Open Access

Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context

GDGerrit DraismaEngineering and Physical Sciences Research Council RERuth EtzioniFred Hutch Cancer Center ATAlex TsodikovUniversity of Michigan

Key Points

Key points are not available for this paper at this time.

Abstract

The precise definition and the population used to estimate lead time and overdiagnosis can be important drivers of study results and should be clearly specified.

AIに質問

Bookmark

View Full Paper

Cite This Study

Draisma et al. (Tue,) studied this question.

synapsesocial.com/papers/69db1d4c4e9a02dbaa684ffa https://doi.org/https://doi.org/10.1093/jnci/djp001

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends2007 · 126 citations
2PROSTATE BIOPSY FOLLOWING A POSITIVE SCREEN IN THE PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER SCREENING TRIAL2005 · 81 citations
3Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute1994 · 213 citations
4On the theory of screening for chronic diseases1969 · 409 citations
5Pathologic and Clinical Findings to Predict Tumor Extent of Nonpalpable (Stage T1 c) Prostate Cancer1994 · 1,807 citations

AIに質問

Bookmark

View Full Paper